Shuttle Pharmaceuticals Holdings (SHPH) Stock Overview
A clinical stage pharmaceutical company, develops novel therapies to cure cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SHPH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Shuttle Pharmaceuticals Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.80 |
| 52 Week High | US$25.25 |
| 52 Week Low | US$1.26 |
| Beta | 0.56 |
| 1 Month Change | 24.14% |
| 3 Month Change | -59.82% |
| 1 Year Change | -92.28% |
| 3 Year Change | -99.49% |
| 5 Year Change | n/a |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| SHPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.7% | -2.0% | -1.4% |
| 1Y | -92.3% | 23.0% | 14.6% |
Return vs Industry: SHPH underperformed the US Biotechs industry which returned 25% over the past year.
Return vs Market: SHPH underperformed the US Market which returned 16% over the past year.
Price Volatility
| SHPH volatility | |
|---|---|
| SHPH Average Weekly Movement | 16.4% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: SHPH's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SHPH's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 9 | Chris Cooper | www.shuttlepharma.com |
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to cure cancers. The company is developing Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas; and SP-2-225, a pre-clinical class IIb product candidate that effects on the regulation of the immune system. It is also developing SP-1-303, a pre-clinical selective Class I HDAC for use in the treatment of ER positive breast cancers; and SP-1-161, a HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway.
Shuttle Pharmaceuticals Holdings, Inc. Fundamentals Summary
| SHPH fundamental statistics | |
|---|---|
| Market cap | US$2.89m |
| Earnings (TTM) | -US$10.71m |
| Revenue (TTM) | n/a |
Is SHPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SHPH income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.71m |
| Earnings | -US$10.71m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 29.9% |
How did SHPH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/02 11:49 |
| End of Day Share Price | 2025/12/31 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shuttle Pharmaceuticals Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.